Atara Biotherapeutics, Inc. (ATRA) vs ImmuCell Corporation (ICCC)

Atara Biotherapeutics, Inc. and ImmuCell Corporation are both Biotechnology companies. Atara Biotherapeutics, Inc. and ImmuCell Corporation are of similar size ($90.6M and $85.7M). Atara Biotherapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 117×. ImmuCell Corporation grew revenue faster over the last twelve months: 8.49% against −96.7%. ImmuCell Corporation has the higher net margin (2.57% vs −269.4%) and the higher return on invested capital (7.84% vs 0.00%). Across the 16 metrics below, ImmuCell Corporation leads on 11 and Atara Biotherapeutics, Inc. on 5.

Valuation

Metric ATRA ICCC Biotechnology median
P/E n/m 117.38 7.88
P/S 21.38 2.93 11.47
P/B n/m 2.87 2.52
Price to free cash flow n/m 21.27 21.16
EV/EBITDA n/m 14.22 0.74
EV/Sales 19.79 2.92 10.73
Earnings yield (13.39%) 0.85% (28.84%)
Free cash flow yield (15.88%) 4.70% (23.03%)

Profitability

Metric ATRA ICCC Biotechnology median
Gross margin 91.38% 40.32% 65.16%
Operating margin (229.67%) 12.60% 0.00%
Net margin (269.42%) 2.57% 0.00%
Free cash flow margin (353.49%) 13.79% 0.00%
Return on equity 46.33% 2.57% (57.72%)
Return on assets (57.62%) 1.69% (49.22%)
Return on invested capital 0.00% 7.84% 0.00%

Growth

Metric ATRA ICCC Biotechnology median
Revenue growth (TTM) (96.72%) 8.49% 5.64%
EPS growth (last fiscal year) 122.52% 53.85% —
Revenue growth, 5-year CAGR — 12.50% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATRA ICCC Biotechnology median
Debt to equity 0.00 0.26 0.00
Current ratio 1.98 4.75 4.73
Net debt to EBITDA (0.22) 1.19 0.96

Dividend

Metric ATRA ICCC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ATRA ICCC Biotechnology median
Market cap 85.72m 90.55m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack